Scarica l'app Stockscreener
13.69
3.48%
0.46
Dopo l'orario di chiusura:
13.69
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.23
Aprire:
$13.37
Volume 24 ore:
64,236
Relative Volume:
0.74
Capitalizzazione di mercato:
$190.05M
Reddito:
$6.67M
Utile/perdita netta:
$-47.55M
Rapporto P/E:
-9.1267
EPS:
-1.5
Flusso di cassa netto:
$-17.44M
1 W Prestazione:
-3.25%
1M Prestazione:
+15.62%
6M Prestazione:
+2,577%
1 anno Prestazione:
+2,577%
Intervallo 1D:
$13.01
$13.80
Intervallo di 1 settimana:
$12.96
$14.74
Portata 52W:
$10.83
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
617-430-5595
Indirizzo
300 FIFTH AVENUE, WALTHAM, CA
Confronta CBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.69 | 190.05M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Iniziato | Jefferies | Buy |
| 2025-08-11 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-14 | Iniziato | Wedbush | Outperform |
| 2025-06-25 | Iniziato | Stifel | Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma to Present at September Investor Conferences - AInvest
Crescent Biopharma (NASDAQ:CBIO) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cancer Drug Developer Crescent Biopharma to Present at Major September Healthcare Conferences - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given Buy Rating at HC Wainwright - Defense World
Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target - Investing.com
Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AInvest
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies Initiates Coverage of Crescent Biopharma with Buy Rating and $26 Price Target - AInvest
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating - Investing.com
Crescent Biopharma shares rise 3.70% intraday after Pyxis Oncology CEO to participate in September investor conferences. - AInvest
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma: Chasing The Summit Hype - Seeking Alpha
Q3 Earnings Forecast for CBIO Issued By HC Wainwright - Defense World
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $25.50 Consensus Target Price from Analysts - Defense World
HC Wainwright Initiates Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Crescent Biopharma Initiated with Buy Rating and $25 Price Target by H.C. Wainwright - AInvest
Analysts Initiate Coverage on Arm Holdings with Bullish Predictions - AInvest
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Benzinga
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Cut to “Sell” at Wall Street Zen - Defense World
Crescent Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crescent Biopharma: Q2 Earnings Snapshot - Greenwich Time
Crescent Biopharma Advances Cancer Therapeutics with CR-001 and ADCs, Completes Merger and Nasdaq Listing - AInvest
Crescent Biopharma's Promising Pipeline and Strategic Positioning Support Buy Rating - AInvest
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
What is Wedbush’s Estimate for CBIO Q2 Earnings? - Defense World
Wedbush Begins Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
Wedbush Initiates Coverage of Crescent Biopharma (CBIO) with Outperform Recommendation - MSN
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Sell Rating - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Galectin Therapeutics shares rise 3.30% premarket after Crescent Biopharma appoints new Chief Scientific Officer. - AInvest
Crescent Biopharma Snatches Oncology Star Jan Pinkas—Here's Why This Could Be a Game-Changer - AInvest
Crescent Biopharma appoints Jan Pinkas as chief scientific officer - Investing.com
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer - GlobeNewswire
ADC Pioneer with ELAHERE Success Record Joins Crescent Biopharma as Chief Scientific Officer - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200 Day Moving Average – Should You Sell? - Defense World
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Biopharma: A Promising Investment in the Growing PD-(L)1-Targeting Market - TipRanks
Crescent Biopharma (CBIO) Receives a New Rating from TD Cowen - The Globe and Mail
Petri Dish: Turkish firm backs Harvard lab, Isomorphic opens in Cambridge - The Business Journals
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):